文献速递乳腺癌

法国多中心ESME队列中40岁以下与40岁以上转移性乳腺癌女性一线真实世界治疗模式与生存结局

First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort.
PubMed 文献 · Eur J Cancer · 2023-11-10

基于法国ESME多中心队列(NCT03275311)2008至2017年确诊的14897例转移性乳腺癌女性(其中1512例<40岁),比较<40岁与40-69岁患者一线治疗模式及总生存(OS)和真实世界无进展生存(rwPFS)。年轻患者TN和HER2+亚型及侵袭性转移更多见,两年龄组预后因素相似。

要点

  • HR+/HER2-为最常见亚型,<40岁与40-69岁患者HR+/HER2-及三阴性mBC一线治疗不同。
  • HR+/HER2- mBC中位OS:<40岁46.9个月 vs 40-69岁46.2个月。
  • 两年龄组OS与rwPFS预后因素相似,包括≥3个转移部位、内脏转移和较长MFI。

核心结论

  • <40岁年轻女性较40-69岁女性更常见TN和HER2+亚型及侵袭性mBC,两年龄组及mBC亚型间OS和rwPFS预后因素相当。

研究设计与样本

  • 数据来自ESME mBC数据库(NCT03275311),纳入2008-2017年在法国18家综合癌症中心连续开始一线转移治疗的成年mBC女性。
  • 共纳入14897例mBC女性,其中1512例年龄<40岁,比较<40岁与40-69岁患者一线治疗策略及OS、rwPFS预后因素。

主要发现

  • HR+/HER2-为最常见亚型,<40岁与40-69岁患者在HR+/HER2-和三阴性mBC中一线治疗不同。
  • HR+/HER2- mBC中位OS:<40岁46.9个月 vs 40-69岁46.2个月;TN mBC:<40岁13.5个月 vs 40-69岁15.2个月;HER2+ mBC:<40岁60.7个月 vs 40-69岁55.1个月。
  • 一线治疗中位rwPFS:HR+/HER2- <40岁11.6个月 vs 40-69岁11.9个月;TN <40岁5.5个月 vs 40-69岁5.9个月;HER2+ <40岁13.3个月 vs 40-69岁12.9个月。
  • 与较短OS和rwPFS相关的因素在<40岁与40-69岁女性中相似,包括≥3个转移部位、内脏转移和较长MFI,多个预后因素观察到时间变化效应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To describe first-line treatment patterns, overall survival (OS) and real-world progression-free survival (rwPFS) in young women (<40) with metastatic breast cancer (mBC), as compared to women aged 40-69. MATERIALS AND METHODS: Data on adult women diagnosed with mBC (2008-2017) were extracted from the ESME mBC database (NCT03275311) which includes consecutive patients starting first-line metastatic treatment in one of the 18 French Comprehensive cancer centers. We reported first-line therapeutic strategy and prognostic factors of OS and rwPFS for women aged < 40 and 40-69. RESULTS: In total, 14,897 mBC women were included (1512 aged <40). HR+ /HER2- mBC was the most frequent subtype. First-line treatment differed between young patients and older ones for HR+ /HER2- and Triple Negative (TN) mBC. Median OS for women aged < 40 and 40-69, respectively, was 46.9 and 46.2 months for HR+ /HER2- mBC; 13.5 and 15.2 for TN mBC; and, 60.7 and 55.1 for HER2 + mBC. Median rwPFS under first line treatment was 11.6 and 11.9 months for HR+ /HER2- in women aged < 40 and 40-69, respectively; 5.5 and 5.9 for TN, and, 13.3 and 12.9 for HER2 + . Factors associated with shorter OS and rwPFS were similar for both women aged < 40 and 40-69 and included ≥ 3 metastatic sites, visceral metastases, and longer MFI, with time-varying effects observed for several prognostic factors. CONCLUSION: Young women presented more frequently with TN and HER2 + subtypes and aggressive mBC than women aged 40-69 did. Prognostic factors of OS and rwPFS were quite similar between age groups and mBC subtypes.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Galvin A, Courtinard C, Bouteiller F, et al. First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort. Eur J Cancer. 2023. PMID: 37977105. doi:10.1016/j.ejca.2023.113422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。